MNS Closes Oversubscribed Financing to Advance Miracus™ Needle-Free Patch Platform into First-in-Human Trials
Leeds, United Kingdom – 01/2026 – MNS, a UK-based medical technology company developing next-generation, needle-free drug delivery solutions, is pleased to announce the close of an oversubscribed financing round.